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Patients with primary immunodeficiency disorders (PID) have an increased risk from acute 
and chronic Epstein–Barr Virus (EBV) viral infections and EBV-associated malignancies. 
Hematopoietic stem cell transplantation (HSCT) is a curative strategy for many patients 
with PID, but EBV-related complications are common in the immediate post-transplant 
period due to delayed reconstitution of T  cell immunity. Adoptive T  cell therapy with 
EBV-specific T cells is a promising therapeutic strategy for patients with PID both before 
and after HSCT. Here we review the methods used to manufacture EBV-specific T cells, 
the clinical outcomes, and the ongoing challenges for future development of the strategy.
Keywords: primary immunodeficiency disorders, epstein–barr virus, adoptive T  cell therapy, immunotherapy, 
hematopoietic stem cell transplantation
BACKGROUND
Epstein–Barr Virus (EBV) is a herpes virus that typically causes a mild to moderate self-limiting 
viral illness in healthy individuals. During primary infection, EBV establishes latency in B lympho-
cytes and oral epithelial cells. The level of B lymphocytes latently infected is maintained at a very 
low level through a potent cell-mediated immune response by EBV-specific T  lymphocytes (1). 
However, individuals with moderate to severe forms of primary immunodeficiency disorders (PID) 
have weakened T-cell immunity with diminished immunosurveillance. PID patients are at risk 
from EBV-related complications which include acute and chronic infections and EBV-associated 
malignancies. EBV is also a frequent inciting factor for hemophagocytic lymphohistiocytosis (HLH) 
in PID with impaired cell-mediated cytotoxicity.
Hematopoietic stem cell transplantation (HSCT) has been used as curative approach for severe 
combined immunodeficiency (SCID) for over 50 years, and the approach is increasingly being used 
for other PIDs (2, 3). However, reconstitution of T cell immunity, needed to control both acquired 
viral infections reactivating viruses, is delayed for up to 6  months after transplantation. During 
this period patients remain extremely vulnerable to viral complications. While antiviral pharma-
cotherapy is available for many of the viruses that contribute to pre- and post-HSCT morbidity 
and mortality, their use is limited by toxicities and emerging resistance. Rituximab, a monoclonal 
antibody targeting CD20, has good efficacy against EBV. However, Rituximab targets not only the 
EBV-infected B cells, but also the healthy B cell compartments, which further weakens the immune 
system. Resistance to rituximab has also been described (4). Given these limitations, adoptive 
therapy with EBV-specific T cells has emerged as a promising therapeutic strategy for PID patients 
with EBV-related complications.
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Adoptive therapy with viral-specific T cells (VSTs) has been 
used for over 20 years (5, 6). Earliest experience using cellular 
therapy for EBV-related post-transplant lymphoproliferative 
disease (PTLD) after HSCT included using unmanipulated donor 
lymphocyte infusions, which was often effective, but carried a 
high risk of graft-versus-host disease (GVHD) (7). Subsequently, 
VSTs have been developed that show safety and efficacy in treat-
ing EBV infections while minimizing the risk of GVHD (8–13). 
While previous reviews have primarily examined the use of all 
forms of VSTs for patients with PID (14, 15), this review focuses 
specifically on the development of and clinical use of EBV-specific 
T cells for patients with PID.
eBv-SPeCiFiC T CeLL GeNeRATiON 
MeTHODS
Several methods have been developed to generate EBV-specific 
T  cell products with minimally alloreactive T  cells to decrease 
the risk of GVHD. These techniques include ex vivo expansion, 
multimer selection, and IFN-γ capture. To date, ex vivo expansion 
is the most commonly used method.
Many ex vivo expansion methods use EBV-transformed 
lymphoblastoid cell lines (LCL) as antigen presenting cells 
(APCs). LCLs are advantageous APCs as they express all 10 EBV 
latency antigens (type III latency), but also high levels of class I 
and II HLA and co-stimulatory molecules (16). Either activated 
monocytes or dendritic cells are used in the first stimulation, 
with LCLs used for subsequent stimulations. To further refine 
this technique, groups have developed methods for modifying 
LCL by either pulsing with synthetic peptide pools encompassing 
viral antigens, or transducing LCLs with adenovirus vectors that 
overexpress either latent membrane protein (LMP) 2 or LMP1 
and LMP2. These strategies enhance T cell specificities for the less 
immunogenic EBV antigens LMP1 and LMP2 increasing their 
efficacy for EBV-related lymphomas that only express LMP1 and 
LMP2 (type II latency). While this method has proven to be safe 
and efficacious, it takes at least 8  weeks to generate a product 
suitable for clinical use as LCL take 3–4 weeks to manufacture. 
This has spurred the development of rapid ex vivo culture meth-
ods using a single stimulation with APC pulsed with synthetic 
peptide pools, or direct stimulation of PBMCs with synthetic 
peptide pools. These methods reduce the manufacturing time to 
10–14 days. Rapid ex vivo culture methods have been used for 
multivirus specific T cells, but not for T cell products specific for 
EBV only.
Additional techniques, such as multimer selection or IFN-γ 
capture, can produce VSTs even more readily than rapid ex vivo 
culture (17–19). Multimer selection uses magnetically labeled 
peptide multimers to isolate T  cells specific for the relevant 
peptide/MHC multimers. IFN-γ capture uses an immunomag-
netic separation device to isolate T  cells that produce IFN-γ 
when stimulated by viral antigens. Although these techniques 
produce a clinical grade product within 48  h, they require 
donors not only to be seropositive to the virus of interest, but 
also to have a detectable level of circulating virus specific T cells. 
Leukapheresis is typically needed to collect enough T cells for 
clinical use. While IFN-γ capture is not HLA-restricted and 
produces a polyclonal and polyfunctional product containing 
CD4+ and CD8+ T cells, multimer selection is an HLA-restricted 
process, and generally yields only CD8+ T cells.
PReviOUS CLiNiCAL USAGe OF eBv-
SPeCiFiC T CeLLS FOR PiD DiSORDeRS
Donor-Derived eBv-Specific T Cells
As PID is one of the most common non-malignant indications 
for referral to HSCT in pediatrics and is associated with high 
risk for viral complications, patients with PID constitute a 
sizeable proportion of patients in VST clinical trials (Table 1). 
A large, multi-center study with a median follow-up of 10 years 
treated 114 patients with EBV-specific T cells after HSCT, either 
for prophylaxis (n = 101) or treatment (n = 13) and included 
13 patients with PID. All patients treated as prophylaxis had 
no subsequent EBV viremia, while three patients with active 
disease attained a complete response (CR) and three additional 
patients achieved a PR (10). Papadopoulou et al. included four 
patients with PID in their clinical trial of multivirus-specific 
T cells (CMV, EBV, AdV, HHV6, BK), two of whom received 
T  cells for EBV-related complications and both of whom 
obtained a CR (20).
In a large retrospective review of 36 PID patients receiving 
VSTs, Naik et  al. included four patients with IL2RG-SCID as 
well as patients with Wiscott–Aldrich and combined immuno-
deficiency disorder (CID) who received donor-derived-specific 
T cells for prophylaxis. All patients remained free of EBV viremia 
after receiving T cells (14). Additionally, one patient with HLH 
received donor-derived trivirus VSTs (CMV, EBV, Adv) for CMV 
and EBV viremia with clearance of both viruses.
Third Party eBv-Specific T Cells
To make cellular therapy more readily available, there is growing 
interest in establishing third-party banks of VSTs. Such T  cell 
therapeutics produced from healthy donors are available for 
“off-the-shelf ” use, eliminating the time and cost associated with 
custom-made products. These would be particularly beneficial 
in the setting of T-cell depleted transplantation, or when EBV-
naive donors are the sole option for an EBV-seropositive patient, 
which would impart high risk of viral reactivation particularly in 
those with prior EBV-associated disease. While there is limited 
experience with third party banks to date, the results have been 
promising, particularly in patients with PID (Table 2).
Vickers et  al. established a large third party bank of EBV-
specific T  cells to treat patients with PTLD and other EBV 
complications after HSCT or solid organ transplantation. To date, 
they have treated three patients with PIDs, including combined 
immune deficiency and chronic granulomatous disease (CGD). 
One patient had a CR, but the other two died from progressive 
disease (PD). At the time of publication, one additional patient 
with CGD had not undergone HSCT, but had EBV-specific T cells 
matched for use after transplantation (22). Two patients with CTP 
synthase 1 (CTPS1) deficiency have been treated with third party 
EBV-specific T cells for EBV-LPD and primary CNS lymphoma, 




indication Specificity Generation method Source Cell Dose Outcomes
Leen et al. (21) SCID Prophylaxis EBV, AdV Culture, 
lymphoblastoid 
cell lines (LCL) with 
Ad5f35 vector
Hematopoietic stem cell 
transplantation (HSCT) donor, 
peripheral blood




GATA2 deficiency EBV, BK CMV, EBV, 
AdV, HHV6, 
BK
Culture, peptide HSCT donor, peripheral blood 2 × 107/m2 CR
SCID variant BK, EBV CMV, EBV, 
AdV, HHV6, 
BK
Culture, peptide HSCT donor, peripheral blood 2 × 107/m2 CR










XLP Prophylaxis EBV Culture, LCL HSCT donor, peripheral blood 2 × 107/m2 No viremia
CID Prophylaxis EBV Culture, LCL HSCT donor, peripheral blood 2.5 × 107/m2 No viremia
WAS Prophylaxis EBV Culture, LCL HSCT donor, peripheral blood 2.5 × 107/m2 No viremia
XLP Prophylaxis EBV Culture, LCL HSCT donor, peripheral blood 2 × 107/m2 No viremia
XLP-like Prophylaxis EBV Culture, LCL HSCT donor, peripheral blood 2 × 107/m2 No viremia
WAS EBV viremia EBV Culture, LCL HSCT donor, peripheral blood 2 × 107/m2 CR
SCAEBV/NK defect EBV viremia EBV Culture, LCL HSCT donor, peripheral blood 1 × 108/m2 CR
SCAEBV EBV viremia EBV Culture, LCL HSCT donor, peripheral blood 2 × 107/m2 PR; died of 
progressive 
lymphoma
SCAEBV EBV viremia EBV Culture, LCL HSCT donor, peripheral blood 2 × 107/m2 No further EBV 
reactivation
XLP (SLAM mutation) EBV viremia EBV Culture, LCL HSCT donor, peripheral blood 2 × 107/m2 CR
XLP EBV viremia EBV Culture, LCL HSCT donor, peripheral blood 2 × 107/m2 PR
XLP EBV viremia EBV Culture, LCL HSCT donor, peripheral blood 2 × 107/m2 CR
XLP EBV viremia EBV Culture, LCL HSCT donor, peripheral blood 2 × 107/m2 PR
Doubrovina 
et al. (12)
XLP EBV-LPD EBV Culture, LCL HSCT donor, peripheral blood 1 × 106/kg × 3 
doses
PD; died
ALPS EBV-LPD EBV Culture, LCL HSCT donor, peripheral blood 1 × 106/kg NE; died
Naik et al. (14) IL2RG-SCID Prophylaxis CMV, EBV, 
AdV
Culture, DC, and 
LCL with Ad5f35f-
CMVpp65 vector
HSCT donor, umbilical cord 1.5 × 107/m2 No viremia
IL2RG-SCID Prophylaxis CMV, EBV, 
AdV
Culture, DC, and 
LCL with Ad5f35f-
CMVpp65 vector
HSCT donor, umbilical cord 2.5 × 107/m2 No viremia
IL2RG-SCID Prophylaxis CMV, EBV, 
AdV
Culture, DC, and 
LCL with Ad5f35f-
CMVpp65 vector
HSCT donor, umbilical cord 1 × 107/m2 No viremia
IL2RG-SCID Prophylaxis CMV, EBV, 
AdV
Culture, DC, and 
LCL with Ad5f35f-
CMVpp65 vector
HSCT donor, umbilical cord 1 × 107/m2 No viremia
WAS Prophylaxis CMV, EBV, 
AdV
Culture, DC, and 
LCL with Ad5f35f-
CMVpp65 vector
HSCT donor 1 × 107/m2 No viremia
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(Continued )
TABLe 2 | Previous clinical use of third party Epstein–Barr Virus (EBV)-specific T cells.
Reference Primary immunodeficiency 
disorders diagnosis
indication Specificity Generation 
method





PTLD EBV Culture, LCL Third party 1–2 × 106/kg/dose; 4 doses 
given weekly
CR
CGD PTLD EBV Culture, LCL Third party 1–2 × 106/kg/dose; 4 doses 
given weekly
PD; died





CTPS1 deficiency Primary CNS 
lymphoma
EBV Culture, LCL Third party 2 × 106/kg/dose; 7 doses given 
weekly; 2 additional doses after 











EBV-LPD CMV, EBV, 
AdV




5 × 106/m2 NR, died from 
EBV-LPD
HLH EBV EBV Culture Third party 2 × 106/kg x 3 doses PR; died of PTLD
CTPS1 deficiency EBV-LPD EBV Culture Third party 2 × 106/kg x 2 doses CR
Withers  
et al. (24)
SCAEBV EBV EBV Culture Third party 2 × 107/m2 EBV: NR; Died
CGD, chronic granulomatous disease; PTLD, post-transplant lymphoproliferative disease; PD, progressive disease; CTPS1, CTP synthase 1 deficiency; EBV-LPD,  




indication Specificity Generation method Source Cell Dose Outcomes
CID Prophylaxis EBV Culture, peptide HSCT donor 2.5 × 107/m2 No viremia
HLH (STXBP2) CMV, EBV CMV, EBV, 
AdV
Culture HSCT donor 1 × 107/m2 × 2 
doses
CMV: CR; EBV: 
CR
WAS Prophylaxis CMV, EBV, 
AdV
Culture HSCT donor 2 × 107/m2 No viremia
SCID, severe combine immunodeficiency; EBV, Epstein–barr virus; AdV, adenovirus; CMV, cytomegalovirus; HHV6, human herpesvirus 6; CR, complete response, HLH, 
hemophagocytic lymphohistiocytosis; NR, no response; XLP, X-linked lymphoproliferative disease; CID, combined immune deficiency; WAS, Wiskott–Aldrich syndrome; SCAEBV, 
severe chronic active EBV; ALPS, autoimmune lymphoproliferative syndrome; DC, dendritic cell.
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and both had CRs after T cell therapy (14, 23). Third party EBV-
specific T cells have also been used in HLH as discussed below.
SPeCiAL CASeS
Pretransplantation
As patients with PID are particularly vulnerable to chronic and 
refractory viral infections even prior to HSCT (25–27), another 
benefit of third party T cells is the ability to treat patients prior 
to transplant. This would not only minimize mortality associated 
with transplant, but could allow more patients to be referred to 
transplant. Naik et al. described two patients with PID (one with 
SCID and another with CTPS1 deficiency) with partially HLA-
matched third-party T  cells prior to HSCT for EBV-LPD, one 
of whom achieved a CR (14, 22, 23). A patient with ADA-SCID 
who developed EBV viremia and CMV colitis while on enzyme 
replacement therapy was treated with trivirus VSTs (CMV, 
EBV, AdV) that were 5/10 HLA matched with the patient, but 
no response was seen and the patient died of EBV-associated 
lymphoma. It was unclear if VST expansion may have been 
compromised in this case by the underlying inherent lympho-
toxicity of ADA deficiency, as patients remain lymphopenic even 
in the setting of optimal enzyme replacement therapy. However, 
the patient with CTPS1 deficiency received 2 doses (2 ×  10E6/
kg/dose) of 9/10 HLA match EBV-specific T cells and attained 
a CR, and underwent subsequent HSCT without further viral 
complications.
HLH with eBv viremia
Hemophagocytic lymphohistiocytosis is condition of hyperin-
flammation associated with immune dysregulation secondary 
to defects in cytotoxic T  lymphocyte and NK  cell function. 
TABLe 1 | Continued
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HLH can be either primary (associated with a known muta-
tion) or secondary, and EBV viremia is a common trigger. In 
particular, familial HLH due to mutations in STXBP2 and PRF1 
have been associated with chronic EBV viremia (28). Other 
PIDs have an increased risk of developing HLH, and several are 
associated with EBV viremia as well as including SAP deficiency, 
XIAP deficiency, ITK deficiency, and CD27 deficiency. While 
EBV typically infects B  cells, EBV-related HLH is frequently 
associated with EBV-infected T cells, which presents therapeutic 
challenges (29). As familial HLH is universally fatal without 
HSCT as definitive treatment, these patients may benefit from 
EBV-directed cell therapy to restore EBV-specific immunity 
early after transplant.
A series of 49 patients who were treated for EBV-LPD follow-
ing HSCT with donor lymphocyte infusion and/or EBV-specific 
VST included three patients with PID: one with autoimmune 
lymphoproliferative syndrome, one with x-linked lymphopro-
liferative disease, and another had primary HLH. There was an 
overall response of 68% following EBV-specific VST infusion, 
including a CR in the patient with HLH who received third party 
EBV-specific T cells (12). Similarly, Papadopoulou et al. reported 
a patient with HLH initially treated with multivirus VSTs for 
HHV6 and BK viremia who subsequently developed EBV reac-
tivation and attained complete clearance of EBV viremia without 
other EBV-directed therapy after T cell infusion (20). The review 
by Naik et al. included two patients with HLH and EBV viremia, 
one of whom attained a CR while the other died of progressive 
EBV-PTLD (14).
Severe Chronic Active eBv
Severe chronic active EBV (SCAEBV) infection is a lymphopro-
liferative disorder characterized by markedly high levels of EBV in 
blood and tissue that often presents with fever, lymphadenopathy, 
hepatic dysfunction, and thrombocytopenia (30). In SCAEBV, 
EBV can infect T and NK cells in addition to B cells. While the 
etiology of SCAEBV is often unknown, the underlying defect may 
represent a type of immunodeficiency. To date, HSCT has shown 
to be the most effective treatment for SCAEBV. As the primary 
problem in SCAEBV is an ineffective immune response to EBV, 
adoptive T  cell therapy with EBV-specific T  cells may be very 
advantageous in this patient population after HSCT. Heslop et al. 
included three patients with SCAEBV (one of whom had a known 
NK cell deficiency) in their trial of 114 patients receiving EBV-
specific T cells. One patient was treated on the prophylactic arm 
and remained free of EBV viremia. Of the two patients with active 
disease at the time of T cell infusion, one patient attained a CR 
while the other died of progressive EBV-associated lymphoma 
(10). Withers et al. reported a patient with SCAEBV who received 
third party EBV-specific T cells but died Day + 14 after infusion 
of PD (24).
CHALLeNGeS AND FUTURe DiReCTiONS
In spite of the successes with EBV-specific T-cells, there remain 
limitations in this approach for treatment of PID. Resistance to 
EBV-specific cellular therapy has been described in several prior 
studies, which may in some cases relate to viral escape mutations. 
In one study, a mutation in EBNA-3B enabled viral escape post-
T-cell therapy (31). The targeted EBV antigens differ slightly 
between trials, and further studies of the lability of targeted 
epitopes will be crucial to improve the efficacy of EBV-specific 
T-cell therapy, particularly in the third-party setting. Best meth-
ods of partial HLA matching of third-party EBV-specific T-cells 
is also unclear, particularly in the setting of rare HLA alleles that 
are not known to mediate recognition of immunodominant EBV 
epitopes. EBV-specific T-cells are also subject to inactivation or 
killing by immunosuppressive therapies, such as corticosteroids, 
which limits their use in the setting of GVHD following HCT. 
Genetic modification of antigen-specific T-cells to render 
them resistant to glucocorticoids and calcineurin inhibitors 
may enable treatment of PTLD in spite of immunosuppressive 
therapy (32, 33).
It is also unclear if adoptive T-cell therapy will be effective 
prior to HCT in forms of PID in which APCs are impaired or 
absent. In a recent study, defects in the costimulatory receptor 
CD70 resulted in EBV-associated disease (34). CD70 defects 
could theoretically impair the ability of allogeneic T-cells to lyse 
infected target cells. EBV-specific T-cells have not been explored 
in patients with EBV-driven HLH prior to HCT, and is unclear 
whether partial restoration of cytotoxicity would be of any benefit 
in this hyper-inflammatory disorder.
Currently, manufacturing of EBV-specific T-cells requires 
a facility with the ability to meet regulatory guidelines for 
production of immune effector cells for clinical use. Selection 
methods allow make use of automated-closed systems, but 
are expensive and yield low cell numbers. Ex vivo expan-
sion yields higher cell numbers, but requires expertise in 
more than minimal product manipulation. In both settings, 
an EBV-seropositive donor would need to be identified for 
product manufacturing. Third party T-cells circumvent these 
limitations, but similarly are limited by cost of bank generation 
and regulatory hurdles that limit widespread availability. New 
multicenter trials using regional banks will improve accessibil-
ity to studies using EBV-specific T-cells. With the recent FDA 
approval of two chimeric antigen receptor T-cell products, it is 
hoped that the use of antigen-specific T-cells may similarly be 
approved in the near future, enabling widespread accessibility 
to these products.
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